An observational study in Dyslipidemia, sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD. — 1 open to participants now, 4 under way, none of them phase 3. Dyslipidemias · Daewoong Pharmaceutical Co. LTD..
Among the 12 studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD., this one is the only one that started in 2026, is one of 7 observational ones, and was the 12th registered.
1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →1 of the 12 studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD. is open now, in 1 country.
By country, each count listing its studies:
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 12,000 is above the median of 660 across 231 observational studies indexed under Dyslipidemias.
Median enrollment 185 across the 5 interventional studies, 9,707 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
1 of the studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07515560Daewoong Pharmaceutical Co. LTD.Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Dyslipidemias by Daewoong Pharmaceutical Co. LTD., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a prospective, non-interventional, multi-center observational study to evaluate the efficacy and safety of Baroezet Tablet 1/10 mg in Korean patients with dyslipidemia in real-world clinical practice.
Patients who are prescribed Baroezet Tablet according to the physician's clinical judgment will be followed for approximately 24 weeks. The study will assess changes in lipid profiles, including LDL-C, as well as safety outcomes such as adverse events.
This study is a prospective, non-interventional, multi-center observational study conducted in Korea to evaluate the efficacy and safety of Baroezet Tablet 1/10 mg (Pitavastatin calcium/Ezetimibe) in patients with dyslipidemia in routine clinical practice.
Eligible patients aged 19 years or older who require treatment with Baroezet Tablet will be enrolled after providing written informed consent. Treatment decisions, including dosage and duration, will be made at the discretion of the treating physician in accordance with approved labeling.
Data will be collected at baseline, approximately 12 weeks, and 24 weeks, based on routine clinical visits. The primary efficacy endpoint is the percent change in LDL-C from baseline to 24 weeks. Secondary endpoints include changes in lipid parameters (TC, TG, HDL-C, non-HDL-C), HbA1c, and achievement of LDL-C targets according to risk categories.
Safety will be assessed by monitoring adverse events and laboratory abnormalities, including liver enzymes and creatine kinase levels.
Approximately 15,000 patients will be enrolled across multiple centers in Korea.
This study will enroll adult patients aged 19 years or older who are diagnosed with dyslipidemia in routine clinical practice in Korea. Eligible patients are those who require treatment with Baroezet Tablet 1/10 mg based on the physician's clinical judgment and provide written informed consent.
Patients will be recruited from multiple centers across Korea in a real-world setting. Treatment decisions, including initiation and continuation of Baroezet Tablet, will be made according to routine clinical practice. Patients with contraindications to the study drug, including hypersensitivity to its components, active liver disease, or pregnancy, will be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with dyslipidemia who are prescribed Baroezet Tablet 1/10 mg according to routine clinical practice will be observed for approximately 24 weeks.
Percent Change in LDL-C from Baseline to Week 24
Percent change in LDL-C levels from baseline to approximately 24 weeks after treatment initiation.
Time frame: Baseline to Week 24
Percent Change in LDL-C at Week 12
Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to approximately 12 weeks after treatment initiation.
Time frame: Baseline to Week 12
Percent Change in Total Cholesterol (TC)
Percent change in total cholesterol (TC) from baseline to approximately 12 weeks after treatment initiation.
Time frame: Baseline to Week 12
Percent Change in Triglycerides (TG)
Percent change in triglyceride (TG) levels from baseline to approximately 12 weeks.
Time frame: Baseline to Week 12
Percent Change in Total Cholesterol (TC)
Percent change in total cholesterol (TC) from baseline to approximately 24 weeks after treatment initiation.
Time frame: Baseline to Week 24
Percent Change in Triglycerides (TG)
Percent change in triglyceride (TG) levels from baseline to approximately 24 weeks.
Time frame: Baseline to Week 24
Start is estimated for Apr 2026; primary completion for Mar 2027, 10 months later.
Of 34 industry-sponsored observational studies under Dyslipidemias, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's planned 10 months is below that.
Counting every sponsor, half of 90 studies reached it within 40 months; a quarter within 23 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD. →